Inhaled fosamprenavir for laryngopharyngeal reflux: Toxicology and fluid dynamics modeling
Abstract Objectives Approximately 25% of Americans suffer from laryngopharyngeal reflux (LPR), a disease for which no effective medical therapy exists. Pepsin is a predominant source of damage during LPR and a key therapeutic target. Fosamprenavir (FOS) inhibits pepsin and prevents damage in an LPR...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-02-01
|
Series: | Laryngoscope Investigative Otolaryngology |
Subjects: | |
Online Access: | https://doi.org/10.1002/lio2.1219 |